Zhongheng Group subsidiary Lummy received the approval notice for the drug supplementary application
I'm LongbridgeAI, I can summarize articles.Zhongheng Group's holding subsidiary Chongqing Lummy Pharmaceutical has received the notification letter for the supplementary application of Clindamycin Phosphate Injection approved by the National Medical Products Administration, involving two specifications: 2ml: 0.3g and 4ml: 0.6g. This medication is primarily used to treat severe infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, and staphylococci
According to the Zhitong Finance APP, Zhongheng Group (600252.SH) announced that its holding subsidiary Chongqing Lummy Pharmaceutical Co., Ltd. (hereinafter referred to as "Lummy Pharmaceutical") has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for two specifications of Clindamycin Phosphate Injection: 2ml: 0.3g and 4ml: 0.6g.
Clindamycin Phosphate Injection is mainly suitable for severe infections caused by sensitive anaerobic bacteria, streptococci, pneumococci, and sensitive strains of staphylococci, as well as specified sensitive microorganisms